Увійти

Готові списки джерел за темами / Human Papillomavirus (HPV) Vaccine / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Human Papillomavirus (HPV) Vaccine.

Статті в журналах з теми "Human Papillomavirus (HPV) Vaccine"

Автор: Grafiati

Опубліковано: 7 червня 2025

Оновлено: 2 серпня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Human Papillomavirus (HPV) Vaccine".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Conageski, Christine. "Human Papillomavirus Vaccines." Clinical Obstetrics & Gynecology 66, no. 3 (2023): 433–47. http://dx.doi.org/10.1097/grf.0000000000000788.

Повний текст джерела

Анотація:

Human papillomavirus (HPV) vaccines are highly effective in preventing the transmission of HPV and thus downstream HPV-related lower genital tract neoplasias. First introduced in 2006, the HPV vaccine has demonstrated clinical efficacy in both men and women. Several commercially available vaccines now exist, but only one is available in the United States. Both prelicensure and postlicensure studies demonstrate robust safety profiles. HPV vaccines should be made available to everyone between the ages of 9 and 26 years of age. Newer vaccination recommendations in expanded populations rely on pat

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Zakhour, Ramia, Hani Tamim, Farah Faytrouni, Maha Makki, Rayan Hojeij, and Lama Charafeddine. "Determinants of human papillomavirus vaccine hesitancy among Lebanese parents." PLOS ONE 18, no. 12 (2023): e0295644. http://dx.doi.org/10.1371/journal.pone.0295644.

Повний текст джерела

Анотація:

Introduction Human papillomavirus (HPV) is the most common sexually transmitted infection. HPV is responsible for cancer of cervix uteri. Despite its safety and immunogenicity, HPV vaccine hesitancy is one of the most challenging topics that pediatricians face. Methods We aimed to describe the impact of knowledge, attitude, and practice towards vaccines in general, on practice related to HPV vaccination in Lebanon. A questionnaire addressed to parents of students (3–18 years of age) was distributed in 2 public and 2 private schools randomly selected from the greater Beirut area during the scho

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Cai, Xia, and Ling Xu. "Human Papillomavirus-Related Cancer Vaccine Strategies." Vaccines 12, no. 11 (2024): 1291. http://dx.doi.org/10.3390/vaccines12111291.

Повний текст джерела

Анотація:

Background: Human papillomavirus (HPV) persistent infection is a major pathogenic factor for HPV-related cancers, such as cervical cancer (CC), vaginal cancer, vulvar cancer, anal cancer, penile cancer, and head and neck cancer (HNC). Since the introduction of the world’s first prophylactic HPV vaccine, there has been a decline in the incidence of HPV infections and associated cancers. This article reviews the latest literature on the research progress, efficacy, and safety of HPV vaccines for these cancers, providing a reference for HPV vaccination strategy. Methods: By utilizing databases su

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Kamolratanakul, Supitcha, and Punnee Pitisuttithum. "Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer." Vaccines 9, no. 12 (2021): 1413. http://dx.doi.org/10.3390/vaccines9121413.

Повний текст джерела

Анотація:

Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15 HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers. However, cervical cancer remains one of the most common cancers in women, especially in developing countries. Three HPV vaccines have been licensed: bivalent (Cervarix, GSK, Rixensart, Belgium), quadrivalent (Merck, Sharp & Dome (Merck & Co, Whitehouse Station, NJ, USA)), and nonavalent (Merck, Sharp & Dome (Merck & Co, Whitehouse Station, NJ, USA)). The current HPV vaccine recommendations apply to 9 years

Стилі APA, Harvard, Vancouver, ISO та ін.

5

de Sanjosé, Silvia, Laia Alemany, Xavier Castellsagué, and F. Xavier Bosch. "Human Papillomavirus Vaccines and Vaccine Implementation." Women's Health 4, no. 6 (2008): 595–604. http://dx.doi.org/10.2217/17455057.4.6.595.

Повний текст джерела

Анотація:

Countries are now challenged by the rapid development of vaccines aimined at the primary prevention of infections. In the years to come, several vaccines will need to be considered as potential candidates in routine immunization programs. Recently, two new vaccines against two/four types of human papillomavirus (HPV) have been commercialized. Bivalent HPV 16 and 18 (Cervarix™) and quadrivalent HPV 6, 11, 16 and 18 (Gardasil®) vaccines are now extensively used in some countries. These vaccines will prevent infection and long-running complications, such as cervical cancer, other HPV-related canc

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Kreimer, Aimée R., Deborah Watson-Jones, Jane J. Kim, and Peter Dull. "Single-dose human papillomavirus vaccination: an update." JNCI Monographs 2024, no. 67 (2024): 313–16. http://dx.doi.org/10.1093/jncimonographs/lgae030.

Повний текст джерела

Анотація:

Abstract Human papillomavirus (HPV) vaccines received regulatory approval and were recommended for use in young girls nearly 2 decades ago. Uptake is mostly high in resource-rich settings. In resource-limited settings, where the burden of cervical cancer is disproportionately high, access to and uptake of HPV vaccines are nowhere near satisfactory, despite evidence that HPV vaccination is highly cost-effective and a significant value-for-money investment. The discovery that only a single dose of the HPV vaccines may be needed to confer adequate protection may make equitable access to HPV vacci

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Toft, Lars, Martin Tolstrup, Merete Storgaard, Lars Østergaard, and Ole S. Søgaard. "Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives." Sexual Health 11, no. 6 (2014): 511. http://dx.doi.org/10.1071/sh14015.

Повний текст джерела

Анотація:

Background Men and women with HIV infection are at increased risk of developing cancers associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines protect against de novo infection with HPV-16 and HPV-18, which cause the majority of HPV-associated cancers. Currently, no vaccine efficacy data are available for persons with HIV infection. Nevertheless, some countries have implemented specific HPV vaccination recommendations for HIV-positive populations. To specifically recommend prophylactic HPV vaccination in people with HIV, the vaccines must be safe and immunogenic

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Cheng, Liqin, Yan Wang, and Juan Du. "Human Papillomavirus Vaccines: An Updated Review." Vaccines 8, no. 3 (2020): 391. http://dx.doi.org/10.3390/vaccines8030391.

Повний текст джерела

Анотація:

Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past decade, have shown promising results in decreasing HPV infection and related diseases, such as warts and precancerous lesions. In this review, we present the updated information about current HPV vaccines, focusing on vaccine coverage and efficacy. In addition, pan-gender vaccination and current clinical trials are also discussed. Currently, more efforts should be put into increasing the vaccine’s coverage, especially in low- and middle-income countries. Provision of education on HPV and vaccination is one

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Stanley, Margaret. "Tumour virus vaccines: hepatitis B virus and human papillomavirus." Philosophical Transactions of the Royal Society B: Biological Sciences 372, no. 1732 (2017): 20160268. http://dx.doi.org/10.1098/rstb.2016.0268.

Повний текст джерела

Анотація:

Two of the most important human oncogenic viruses are hepatitis B virus (HBV) and human papillomavirus (HPV). HBV infection has been preventable by vaccination since 1982; vaccination of neonates and infants is highly effective, resulting already in decreased rates of new infections, chronic liver disease and hepato-cellular carcinoma. Nonetheless, HBV remains a global public health problem with high rates of vertical transmission from mother to child in some regions. Prophylactic HPV vaccines composed of virus-like particles (VLPs) of the L1 capsid protein have been licensed since 2006/2007.

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Garland, Suzanne M. "Human papillomavirus vaccines: challenges to implementation." Sexual Health 3, no. 2 (2006): 63. http://dx.doi.org/10.1071/sh06018.

Повний текст джерела

Анотація:

Clinical trials for prophylactic human papillomavirus (HPV) vaccines have shown overwhelmingly positive results. It is expected that with good coverage of the vaccine, 70% of cervical cancers will be prevented, as will a proportion of other HPV-related anogenital diseases. Issues that will require careful consideration will include: whether males and females should be vaccinated; the durability of the immune response; the proportion of attributable disease to the HPV types targetted by the vaccines; and accessibility and cost of the vaccine. Central to an effective vaccination programme will b

Стилі APA, Harvard, Vancouver, ISO та ін.

11

KAWANA, Kei. "Human papillomavirus prophylactic vaccine." Uirusu 62, no. 1 (2012): 79–86. http://dx.doi.org/10.2222/jsv.62.79.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Gürbüz, Tuğba, and İlkiz Özge Özdil Yılmaz. "Human papillomavirus vaccines in obstetrics and pediatrics: a comprehensive review." Journal of Controversies in Obstetrics & Gynecology and Pediatrics 3, no. 3 (2025): 68–73. https://doi.org/10.51271/jcogp-0052.

Повний текст джерела

Анотація:

Human papillomavirus (HPV) is a highly prevalent infection with significant implications for global public health, particularly in obstetric and pediatric populations. Persistent infection with high-risk HPV genotypes, such as HPV-16 and HPV-18, is a leading cause of cervical cancer, a major contributor to cancer-related mortality worldwide. Beyond cervical malignancies, HPV is etiologically linked to anal, vulvar, vaginal, penile, and oropharyngeal carcinomas. Additionally, it is responsible for benign but distressing conditions such as genital warts, imposing substantial psychosocial and eco

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Getova-Kolarova, Violeta, Albena Zlatareva, and Ivo Kumanov. "Exploring the nexus of trust, information sources, and vaccination intent: a study of HPV awareness and general practitioner influence." Pharmacia 71 (June 7, 2024): 1–6. http://dx.doi.org/10.3897/pharmacia.71.e122666.

Повний текст джерела

Анотація:

This study delves into the intricate interplay between trust in personal doctors (GPs), sources of information about recommended vaccines, and the willingness to vaccinate against human papillomavirus (HPV) and other recommended vaccines. The analysis revealed a positive and statistically significant correlation between HPV awareness and the willingness to vaccinate. Notably, awareness concerning HPV is high, with 35.6% of all respondents expressing readiness to receive the HPV vaccine. The study identified the personal doctor as the predominant source of vaccine-related information. The ident

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Getova-Kolarova, Violeta, Albena Zlatareva, and Ivo Kumanov. "Exploring the nexus of trust, information sources, and vaccination intent: a study of HPV awareness and general practitioner influence." Pharmacia 71 (June 7, 2024): 1–6. https://doi.org/10.3897/pharmacia.71.e122666.

Повний текст джерела

Анотація:

This study delves into the intricate interplay between trust in personal doctors (GPs), sources of information about recommended vaccines, and the willingness to vaccinate against human papillomavirus (HPV) and other recommended vaccines. The analysis revealed a positive and statistically significant correlation between HPV awareness and the willingness to vaccinate. Notably, awareness concerning HPV is high, with 35.6% of all respondents expressing readiness to receive the HPV vaccine. The study identified the personal doctor as the predominant source of vaccine-related information. The ident

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Gökhan Doğukan, Akarsu, Akarsu Rukiye Höbek, Sungur Neslihan, and Tufanoğlu Nur. "Human papillomavirus: What we know and what we doing?" Archives of Community Medicine and Public Health 9, no. 1 (2023): 004–10. http://dx.doi.org/10.17352/2455-5479.000194.

Повний текст джерела

Анотація:

Aim: In this study, it was aimed to determine the thoughts and attitudes of young adults about HPV and HPV vaccines. Methods: This study was planned as a cross-sectional study to determine the knowledge levels and attitudes of young people living in a settlement in the middle of Turkey about the HPV vaccine. The research was conducted with 870 young adults between 1-30 November 2022. Results: The average age of the young people participating in the study was 20.49 ± 2.15 years, 60.9% of them were male. 61% have not heard of the PAP-Smear test before, 51.3% do not know what HPV is, only 17.7% h

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Williamson, Anna-Lise. "Recent Developments in Human Papillomavirus (HPV) Vaccinology." Viruses 15, no. 7 (2023): 1440. http://dx.doi.org/10.3390/v15071440.

Повний текст джерела

Анотація:

Human papillomavirus (HPV) is causally associated with 5% of cancers, including cancers of the cervix, penis, vulva, vagina, anus and oropharynx. The most carcinogenic HPV is HPV-16, which dominates the types causing cancer. There is also sufficient evidence that HPV types 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 cause cervical cancer. The L1 protein, which, when assembled into virus-like particles, induces HPV-type-specific neutralising antibodies, forms the basis of all commercial HPV vaccines. There are six licensed prophylactic HPV vaccines: three bivalent, two quadrivalent and one no

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Rahayu, Sri, Fitriani Nur Damayanti, Mas Ayu Thesi Defalia, Heni Betri, and Eradian Ambarwulan. "Bibliometric Analysis of Vaccine Trends and Novelty to Prevent Human Papillomavirus (HPV) Infection in Pregnant Women." Jurnal Kebidanan 14, no. 1 (2025): 68. https://doi.org/10.26714/jk.14.1.2025.68-78.

Повний текст джерела

Анотація:

Human papillomavirus (HPV) is the most common viral infection of the genital tract. Human papillomavirus (HPV) is associated with cervical, vulvar, and vaginal cancers in women, penile cancer in men, anal cancer, and oropharyngeal cancer in both. The biomolecular profile of Human Papillomavirus (HPV) has been widely studied in patients treated for HPV-related cervical lesions. Prophylactic vaccination against HPV is recommended as part of the vaccination schedule in many countries. This study aims to determine the trend in the number of publications, visualization of the relationship between t

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Kahn, Jessica A., Susan L. Rosenthal, Tara Hamann, and David I. Bernstein. "Attitudes about human papillomavirus vaccine in young women." International Journal of STD & AIDS 14, no. 5 (2003): 300–306. http://dx.doi.org/10.1258/095646203321605486.

Повний текст джерела

Анотація:

Human papillomavirus (HPV) vaccines are under investigation, but little is known about attitudes regarding vaccination. The aims of this study were to identify attitudes about and intention to receive an HPV vaccine in young women using a theory-based model. Young women ( n=52, mean age 25 years, range 18-30 years, 35% Black/Non-Hispanic) completed a survey assessing knowledge, attitudes about HPV vaccination, and risk behaviours. Associations between attitudes and intention to receive the vaccine were assessed using Mann-Whitney U or chi-square tests. Subjects reported positive attitudes abou

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Erden, Ezgi Eda, and Özlem Oyardi. "Human Papillomavirus (HPV) Vaccines: A Comprehensive Review." Journal of European Internal Medicine Professionals (JEIMP) 3, no. 1 (2025): 41–46. https://doi.org/10.5281/zenodo.14775953.

Повний текст джерела

Анотація:

<em>Human papillomavirus</em> (HPV) is a double-stranded DNA virus from the Papillomaviridae family that primarily infects basal epithelial cells. This virus is responsible for causing warts, papillomas, and various cancers in both men and women. To date, over 200 HPV types have been identified, which are classified into high-risk and low-risk categories. High-risk types, such as HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are known to contribute significantly to cancer development. Among these, HPV 16 and 18 are the most common and are strongly associated with the onset

Стилі APA, Harvard, Vancouver, ISO та ін.

20

He, Wei, Haiying Pan, Bing Lin, and Xiaoni Zhong. "Analysis of HPV Vaccination Willingness amongst HIV-Negative Men Who Have Sex with Men in China." Vaccines 9, no. 10 (2021): 1069. http://dx.doi.org/10.3390/vaccines9101069.

Повний текст джерела

Анотація:

Objective: Men who have sex with men (MSM) are high-risk groups of human papillomavirus (HPV) infection, the best measure to prevent this is the HPV vaccine. However, few studies have investigated HPV vaccination willingness in the MSM population in China. We aimed to explore the willingness of human immunodeficiency virus (HIV)-negative MSM for HPV vaccination and the factors affecting their willingness to vaccinate. Methods: We adopted a non-probability sampling method to recruit HIV-negative MSM volunteers. Participants completed a questionnaire, including sociodemographic characteristics,

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Dobrokhotova, Yuliya E., and Ekaterina I. Borovkova. "Human papillomavirus vaccination: evidence base for efficacy and safety." Gynecology 23, no. 2 (2021): 125–30. http://dx.doi.org/10.26442/20795696.2021.2.200742.

Повний текст джерела

Анотація:

The article provides a literature review on the prevention of cervical cancer by human papillomavirus (HPV) vaccination. Currently, 3 vaccines are available: the 4-valent vaccine against HPV types 6, 11, 16 and 18, the 9-valent vaccine against HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 and the bivalent vaccine against HPV types 16 and 18. Vaccination provides protection for women and men against infection with HPV and further development of HPV-associated diseases. Following immunization, seroconversion develops in 93-100% of women and in 99-100% of men and is effective in preventing incident

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Gutierrez, Baudelio, Anthony Leung, Kevin Trimell Jones, et al. "Acceptability of the Human Papillomavirus Vaccine Among Urban Adolescent Males." American Journal of Men's Health 7, no. 1 (2012): 27–36. http://dx.doi.org/10.1177/1557988312456697.

Повний текст джерела

Анотація:

The human papillomavirus (HPV) vaccine was recently approved for use in males. Certain groups, such as men who have sex with men (MSM), are at increased risk of HPV infection. The purpose of the study was to understand perceptions of HPV and the vaccine among adolescent and young adult males, both heterosexual and MSM. Seventy-six males (45 heterosexual, 31 MSM) completed a questionnaire and participated in a focus group. Overall, 42% had heard of HPV and 39% had heard of the HPV vaccine. Males had moderate to favorable attitudes toward vaccination, although intentions to vaccinate were more n

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Lelliott, Madoka, Ethan Sahker, and Hemant Poudyal. "A Review of Parental Vaccine Hesitancy for Human Papillomavirus in Japan." Journal of Clinical Medicine 12, no. 5 (2023): 2004. http://dx.doi.org/10.3390/jcm12052004.

Повний текст джерела

Анотація:

Globally, Japan has the lowest rate of vaccine confidence. The persistent parental vaccine hesitancy has been attributed to safety and efficacy concerns and is primarily driven by the negative experience with human papillomavirus (HPV) vaccines. This literature review aimed to identify factors associated with HPV vaccine uptake and potential strategies to reduce vaccine hesitancy among Japanese parents. Articles published in English or Japanese between January 1998 and October 2022 that examined Japanese parental factors for HPV vaccine uptake were identified from PubMed, Web of Science, and I

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Mejia, Andres F., Timothy D. Culp, Nancy M. Cladel, et al. "Preclinical Model To Test Human Papillomavirus Virus (HPV) Capsid Vaccines In Vivo Using Infectious HPV/Cottontail Rabbit Papillomavirus Chimeric Papillomavirus Particles." Journal of Virology 80, no. 24 (2006): 12393–97. http://dx.doi.org/10.1128/jvi.01583-06.

Повний текст джерела

Анотація:

ABSTRACT A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both h

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Akhatova, Ayazhan, Azliyati Azizan, Kuralay Atageldiyeva, et al. "Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State." Vaccines 10, no. 11 (2022): 1912. http://dx.doi.org/10.3390/vaccines10111912.

Повний текст джерела

Анотація:

Immunization is the most successful method in preventing and controlling infectious diseases, which has helped saving millions of lives worldwide. The discovery of the human papillomavirus (HPV) infection being associated with a variety of benign conditions and cancers has driven the development of prophylactic HPV vaccines. Currently, four HPV vaccines are available on the pharmaceutical market: Cervarix, Gardasil, Gardasil-9, and the recently developed Cecolin. Multiple studies have proven the HPV vaccines’ safety and efficacy in preventing HPV-related diseases. Since 2006, when the first HP

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Korovkin, A. S., T. N. Nikitina, T. Yu Kozlova, D. V. Gorenkov, and A. R. Volgin. "Human papillomavirus vaccines: organisation and experience of preclinical studies." Biological Products. Prevention, Diagnosis, Treatment 24, no. 3 (2024): 243–54. http://dx.doi.org/10.30895/2221-996x-2024-24-3-243-254.

Повний текст джерела

Анотація:

INTRODUCTION. Vaccination is the main measure for the primary prevention of human papillomavirus (HPV)-related diseases. The development of novel vaccine candidates is underway worldwide, including in the Russian Federation. At the same time, the clinical introduction of new HPV vaccines is seriously hampered by the lack of clear and unambiguous recommendations for conducting preclinical studies of these vaccines.AIM. This study aimed to analyse regulatory documents on HPV vaccines, to study the experience of conducting preclinical studies, and to summarise the preclinical approaches that coul

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Flaherty, Dennis K., and Fadi M. Alkhateeb. "Human Papillomavirus Quadrivalent Vaccine: A Look Behind The Numbers." Annals of Pharmacotherapy 43, no. 4 (2009): 740–44. http://dx.doi.org/10.1345/aph.1l483.

Повний текст джерела

Анотація:

The human papillomavirus (HPV) quadrivalent vaocine was licensed in 2006 for prevention of cervical, vulvar, and vaginal cancers caused by HPV-16 and −18 and genital warts caused by HPV-6 and −11. It is also indicated for prevention of precancerous and dysplastic lesions caused by HPV-6, −11, −16, and −18. Questions exist about the number of women and girls infected with the HPV strains covered by the vaccine, as well as about the vaccine's cost-effectiveness. There are also concerns about the efficacy of the vaccine in girls and young women, the population impact of the vaccine, the duration

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Manolescu, Loredana Sabina Cornelia, Corina Zugravu, Corneliu Nicolae Zaharia, et al. "Barriers and Facilitators of Romanian HPV (Human Papillomavirus) Vaccination." Vaccines 10, no. 10 (2022): 1722. http://dx.doi.org/10.3390/vaccines10101722.

Повний текст джерела

Анотація:

Background: Many countries had initial success with HPV vaccination campaigns worldwide. The HPV vaccine coverage during the COVID-19 pandemic dropped consistently. The aim of our research is to assess the barriers and facilitators of the current Romanian HPV vaccination campaign. Methods: An analytical cross-sectional observational survey was conducted in the Romanian general population; a self-administered questionnaire was used. Results: 1122 responders were interviewed; 666 (59.36%) were parents, and 67 (5.97%) HPV vaccinated themselves. A multinominal logistic regression carried out in th

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Awua, Adolf K., Alberto Severini, Edwin K. Wiredu, Edwin A. Afari, Vanessa A. Zubach, and Richard M. K. Adanu. "Self-Collected Specimens Revealed a Higher Vaccine- and Non-Vaccine-Type Human Papillomavirus Prevalences in a Cross-Sectional Study in Akuse." Advances in Preventive Medicine 2020 (January 22, 2020): 1–13. http://dx.doi.org/10.1155/2020/8343169.

Повний текст джерела

Анотація:

Background. Population-specific epidemiologic data on human Papillomavirus infection, which are limited in most of the SubSaharan African countries, are necessary for effective cervical cancer prevention. This study aimed to generate population-specific data on human Papillomavirus infections, and determine which of these, self-collected and provider-collected specimens, gives a higher estimate of the prevalence of human Papillomaviruses, including vaccine and non-vaccine-type human Papillomavirus. Methods. In this cross-sectional study, following a questionnaire-based collection of epidemiolo

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Barry, Victoria, Shannon B. Myers, Amy E. Sgrenci, Megan Lavery, Deirdra Frum, and Erin L. O'Hea. "Sexual Health Variables and the Human Papillomavirus Vaccine." Californian Journal of Health Promotion 7, no. 2 (2009): 129–38. http://dx.doi.org/10.32398/cjhp.v7i2.2021.

Повний текст джерела

Анотація:

Recent strides have been made in developing vaccines to prevent contraction of the Human Papillomavirus (HPV), which is currently the most prevalent sexually transmitted disease in the United States. This study looked to investigate seven sexually relevant variables hypothesized to be related to a young woman's choice to receive the Gardasil® vaccine in order to prevent HPV contraction via a cross sectional survey. In a sample of 77 undergraduate women, we investigated the relationship between receipt of Gardasil® and the following variables: knowledge regarding HPV, relationship status, seeki

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Nghi, Nguyen Quy, D. Scott LaMontagne, Allison Bingham, et al. "Human papillomavirus vaccine introduction in Vietnam: formative research findings." Sexual Health 7, no. 3 (2010): 262. http://dx.doi.org/10.1071/sh09123.

Повний текст джерела

Анотація:

Background: Formative research is a useful tool for designing new health interventions. This paper presents key findings from formative research conducted in Vietnam to guide human papillomavirus (HPV) vaccine introduction. Methods: We explored the sociocultural environment, health system capacity and the policy-making process using a combined quantitative and qualitative methodology. Data collection was done through literature review, in-depth interviews, focus group discussions, observation checklists and a structured questionnaire on knowledge, attitudes and practices. Populations of intere

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Choi, Jihye, Efrat K. Gabay, and Paula M. Cuccaro. "School Teachers’ Perceptions of Adolescent Human Papillomavirus (HPV) Vaccination: A Systematic Review." Vaccines 12, no. 4 (2024): 361. http://dx.doi.org/10.3390/vaccines12040361.

Повний текст джерела

Анотація:

School nurses are uniquely positioned to educate students about immunizations, including human papillomavirus (HPV) vaccination, but schools are often without a nurse for different reasons. In lieu of nurses, teachers who closely interact with students and are traditionally well-trusted by parents may be able to communicate about HPV vaccination, alleviating parental vaccine hesitancy. This systematic review explores school teachers’ perspectives on adolescent HPV vaccination and factors influencing their willingness to make vaccine recommendations. We searched three databases with appropriate

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Zeglin, Robert J., and Juliet L. Fetteroll. "Human papillomavirus vaccine timing associated with eventual human papillomavirus diagnosis in women." International Journal of STD & AIDS 31, no. 10 (2020): 976–81. http://dx.doi.org/10.1177/0956462420937168.

Повний текст джерела

Анотація:

Nearly all cases of cervical cancer are attributable to human papillomavirus (HPV), making it a significant women’s health issue. Though there have been advances in the prevention of HPV via vaccination, significant barriers continue to suppress vaccination rates for girls. Delaying vaccination until after sexual debut increases a woman’s chance of HPV infection, but there has been no quantification of this risk in the literature. The present study sought to address this gap via secondary data analysis with 173 female participants from the 2015–2016 National Health and Nutrition Examination Su

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Redd, David S., Jamie L. Jensen, Savannah J. Hughes, et al. "Effects of Religious Practice and Teachings about Sexual Behavior on Intent to Vaccinate against Human Papillomavirus." Vaccines 10, no. 3 (2022): 397. http://dx.doi.org/10.3390/vaccines10030397.

Повний текст джерела

Анотація:

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. Most infections are mild and clear without treatment in 1 to 2 years. Some HPV strains result in persistent infection, which can cause various cancers, including cervical, penile, anal, mouth, and throat cancers. Vaccines have been developed that provide protection against the highest risk HPV strains. Despite HPV vaccines having been proven to be safe and effective, uptake has been low. Religiosity has been negatively correlated with HPV vaccine uptake in some studies. It is hypothesized that re

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Tomaszewski, Tre, Alex Morales, Ismini Lourentzou, et al. "Identifying False Human Papillomavirus (HPV) Vaccine Information and Corresponding Risk Perceptions From Twitter: Advanced Predictive Models." Journal of Medical Internet Research 23, no. 9 (2021): e30451. http://dx.doi.org/10.2196/30451.

Повний текст джерела

Анотація:

Background The vaccination uptake rates of the human papillomavirus (HPV) vaccine remain low despite the fact that the effectiveness of HPV vaccines has been established for more than a decade. Vaccine hesitancy is in part due to false information about HPV vaccines on social media. Combating false HPV vaccine information is a reasonable step to addressing vaccine hesitancy. Objective Given the substantial harm of false HPV vaccine information, there is an urgent need to identify false social media messages before it goes viral. The goal of the study is to develop a systematic and generalizabl

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Katz, Ingrid T., Norma C. Ware, Glenda Gray, Jessica E. Haberer, Claude A. Mellins, and David R. Bangsberg. "Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence." Sexual Health 7, no. 3 (2010): 279. http://dx.doi.org/10.1071/sh09130.

Повний текст джерела

Анотація:

This review article provides a conceptual framework for human papillomavirus (HPV) vaccine acceptance and adherence, with a focus on improving understanding of the sociocultural factors impacting vaccine adherence behaviour. We include a systematic review of the slowly expanding literature on HPV vaccine acceptability and uptake in developed nations, as well as the relatively few publications from poorer nations, where more than 80% of global cervical cancer related deaths occur and where the vaccine will probably have the largest impact. We suggest that this conceptual framework will not only

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Prabhu, Priya R., Joseph J. Carter, and Denise A. Galloway. "B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination." Vaccines 10, no. 6 (2022): 837. http://dx.doi.org/10.3390/vaccines10060837.

Повний текст джерела

Анотація:

Infection with human papillomavirus (HPV) is the necessary cause of cervical cancer. Availability of vaccines against HPV makes it a highly preventable disease. HPV vaccines act through type-specific neutralizing antibodies produced by antigen-specific plasma cells known as long-lived plasma cells (LLPC). However, just as any other vaccine, success of HPV vaccine is attributed to the immunologic memory that it builds, which is largely attained through generation and maintenance of a class of B cells named memory B cells (Bmem). Both LLPCs and Bmems are important in inducing and maintaining imm

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Jensen, JaNiese E., Greta L. Becker, J. Brooks Jackson, and Mary B. Rysavy. "Human Papillomavirus and Associated Cancers: A Review." Viruses 16, no. 5 (2024): 680. http://dx.doi.org/10.3390/v16050680.

Повний текст джерела

Анотація:

The human papillomavirus is the most common sexually transmitted infection in the world. Most HPV infections clear spontaneously within 2 years of infection; however, persistent infection can result in a wide array of diseases, ranging from genital warts to cancer. Most cases of cervical, anal, and oropharyngeal cancers are due to HPV infection, with cervical cancer being one of the leading causes of cancer death in women worldwide. Screening is available for HPV and cervical cancer, but is not available everywhere, particularly in lower-resource settings. HPV infection disproportionally affec

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Omayo, L. N., O. O. Malande, A. M. Musyoki, P. X. Hoffman, and V. E. Adamu. "Determinants of human papillomavirus (HPV) vaccine hesitancy in sub-Saharan Africa: A systematic review." Journal of the African Society for Paediatric Infectious Diseases 2 (December 30, 2023): 1–29. https://doi.org/10.15641/jafspidvol2pp1-29/1666.

Повний текст джерела

Анотація:

Background: Vaccine hesitancy is a major public health issue that has negatively impacted vaccine uptake in sub-Saharan Africa (SSA). The reasons why individuals hesitate or refuse to vaccinate are variable and factors contributing to vaccine hesitancy are not well outlined. This review, therefore, aims to identify and describe the determinants of HPV vaccine hesitancy in SSA.Methods: A systematic search was conducted across four electronic databases (PubMed, Scopus, CINAHL and Web of Science) from 2007 until October 2021 and updated in January 2022. Following the Preferred Reporting Items for

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Akçaoğlu, Tuğba, Elif Ucar, and Ozan Dogan. "Evaluation of patient awareness of 4v and 9v HPV vaccines: A Turkish survey." Journal of Surgery and Medicine 9, no. 1 (2024): 00. https://doi.org/10.28982/josam.7811.

Повний текст джерела

Анотація:

Background/Aim: The 9-valent (9v) Human Papillomavirus (HPV) vaccine was implemented in Turkey in December 2022 and has just started to be applied. The vaccine is intended to protect against diseases caused by Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Awareness of vaccines in Turkey can be improved through physicians’ and health workers’ efforts, social media and other communication channels. Methods: To guide awareness-raising efforts pertaining to vaccines, we asked our patients who applied for the HPV vaccine at the beginning of 2023 to answer a questionnaire.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Ganesh Kumar, S., P. Krupakar, J. Sakthivel, and P. Chirayu. "Designing of a novel and potent HPV66 L1 major capsid protein-epitope based therapeutic vaccine against Human Papillomavirus (HPV): A bioinformatics approach." Journal of Environmental Biology 45, no. 2 (2024): 130–38. http://dx.doi.org/10.22438/jeb/45/2/mrn-5248.

Повний текст джерела

Анотація:

Aim: Oncogenic human papillomaviruses (HPV) cause various types of cancer, including cervical cancer. The main protein of HPV is capsid, targeted in many vaccine attempts. However, these vaccines do not cover enough high-risk HPV serotypes. Therefore, a low-cost potential HPV vaccine to protect against all serovars of the α-papillomaviruses family would be promising in the future. Our study aimed to develop a therapeutic epitope vaccine for HPV using bioinformatics methods. Methodology: Bioinformatics approach was followed to analyze and identify potential T-cell and B-cell dominant epitopes o

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Toh, Zheng Quan, Chau Quang, Joseph A. Tooma, Suzanne M. Garland, Kim Mulholland, and Paul V. Licciardi. "Australia’s Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific." Vaccines 9, no. 8 (2021): 921. http://dx.doi.org/10.3390/vaccines9080921.

Повний текст джерела

Анотація:

Australian researchers have made substantial contributions to the field of vaccinology over many decades. Two examples of this contribution relate to pneumococcal vaccines and the human papillomavirus (HPV) vaccine, with a focus on improving access to these vaccines in low- and lower-middle-income countries (LLMICs). Many LLMICs considering introducing one or both of these vaccines into their National Immunisation Programs face significant barriers such as cost, logistics associated with vaccine delivery. These countries also often lack the resources and expertise to undertake the necessary st

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Xu, Dan, Jia-Dai Li, Jiao An, et al. "A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine." Vaccines 12, no. 12 (2024): 1356. https://doi.org/10.3390/vaccines12121356.

Повний текст джерела

Анотація:

Background: Cervical cancer is associated with persistent infection of high-risk human papillomaviruses (HPVs). Prophylactic HPV vaccines have been recommended and have significant efficacy in preventing cervical cancer. Multivalent HPV vaccines have a better preventative effect on HPV-related diseases. However, there is currently only one nine-valent HPV vaccine on the market: Gardasil® 9. The development of new HPV vaccines is still urgent in order to achieve the goal of eliminating cervical cancer as proposed by the WHO. Methods: In this study, we developed a nine-valent recombinant HPV vir

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Harrell, Heather. "Currents in Contemporary Ethics." Journal of Law, Medicine & Ethics 37, no. 1 (2009): 134–38. http://dx.doi.org/10.1111/j.1748-720x.2009.00357.x.

Повний текст джерела

Анотація:

The Human Papillomavirus (HPV) vaccine burst onto the market and the legislative scene nearly simultaneously. Marketed as an amazing medical breakthrough, the vaccine GARDASIL prevents infection with four strains of Human Papillomavirus in nave populations; these four strains are responsible for 70% of cervical cancers and 90% of genital warts. Although most agreed that the vaccine was a wonderful medical advancement with the potential to save women's lives, there was strong disagreement about and a vocal public response to legislative attempts to require girls to receive HPV vaccines for scho

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Peralta, Raúl, Cruz Vargas-De-León, Augusto Cabrera, and Pedro Miramontes. "Dynamics of High-Risk Nonvaccine Human Papillomavirus Types after Actual Vaccination Scheme." Computational and Mathematical Methods in Medicine 2014 (2014): 1–8. http://dx.doi.org/10.1155/2014/542923.

Повний текст джерела

Анотація:

Human papillomavirus (HPV) has been identified as the main etiological factor in the developing of cervical cancer (CC). This finding has propitiated the development of vaccines that help to prevent the HPVs 16 and 18 infection. Both genotypes are associated with 70% of CC worldwide. In the present study, we aimed to determine the emergence of high-risk nonvaccine HPV after actual vaccination scheme to estimate the impact of the current HPV vaccines. A SIR-type model was used to study the HPV dynamics after vaccination. According to the results, our model indicates that the application of the

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Poole, Brian D., David S. Redd, Jessica D. Altman, et al. "Culturally-specific education can change perception of risk of Human Papillomavirus infection and need for vaccination." Journal of Immunology 210, no. 1_Supplement (2023): 252.10. http://dx.doi.org/10.4049/jimmunol.210.supp.252.10.

Повний текст джерела

Анотація:

Abstract Safe and effective vaccines have been developed that protect against high-risk strains of HPV, but uptake is relatively low. We previously identified factors such as sexual attitudes and HPV knowledge that impact the intent of Christian parents to vaccinate their children against HPV. One of the major factors that decreased vaccine utilization was the belief that they did not need to vaccinate their children because of their moral beliefs. We hypothesized that culturally specific interventions in the form of short videos would be effective at improving HPV vaccine attitudes. We made t

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Murillo, Raúl, and Camila Ordóñez- Reyes. "Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs." International Journal of Gynecologic Cancer 29, no. 8 (2019): 1317–26. http://dx.doi.org/10.1136/ijgc-2019-000582.

Повний текст джерела

Анотація:

Cervical cancer incidence and mortality have decreased in high-income countries, but low- and middle-income countries continue to bear a significant burden from the disease. Human papillomavirus (HPV) vaccines are a promising alternative for disease control; however, their introduction is slow in settings with greater need. We conducted a review of HPV vaccine efficacy and effectiveness reported in clinical trials and population-based studies. Efficacy of HPV vaccines is close to 100% when using a three-dose schedule in HPV-negative young women (<25 years old) for protection against persist

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Naucler, Pontus, Flora Mabota da Costa, Otto Ljungberg, Antonio Bugalho, and Joakim Dillner. "Human papillomavirus genotypes in cervical cancers in Mozambique." Journal of General Virology 85, no. 8 (2004): 2189–90. http://dx.doi.org/10.1099/vir.0.80001-0.

Повний текст джерела

Анотація:

The distribution of human papillomavirus (HPV) types in cervical cancers is essential for design and evaluation of HPV type-specific vaccines. To follow up on a previous report that HPV types 35 and 58 were the dominant HPV types in cervical neoplasia in Mozambique, the HPV types in a consecutive case series of 74 invasive cervical cancers in Mozambique were determined. The most common worldwide major oncogenic HPV types 16 and 18 were present in 69 % of cervical cancers, suggesting that a vaccine targeting HPV-16 and -18 would have a substantial impact on cervical cancer also in Mozambique.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Lee, Lai-yang, and Suzanne M. Garland. "Human papillomavirus vaccination: the population impact." F1000Research 6 (June 12, 2017): 866. http://dx.doi.org/10.12688/f1000research.10691.1.

Повний текст джерела

Анотація:

We currently have the knowledge and experience to prevent much of human papillomavirus (HPV)-related disease burden globally. In many countries where prophylactic HPV vaccination programs have been adopted as highly effective public health programs with good vaccine coverage, we are already seeing, in real-world settings, reduction of vaccine-related HPV-type infections, genital warts and cervical pre-cancers with potential reductions in vulvar, vaginal and anal pre-cancers. Moreover, we are seeing a change in cervical screening paradigms, as HPV-based screening programs now have strong eviden

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Adjei Boakye, Eric, Dina K. Abouelella, Mrudula Nair, and Nosayaba Osazuwa-Peters. "Human papillomavirus (HPV) vaccine hesitancy trends in the United States." Journal of Clinical Oncology 40, no. 16_suppl (2022): 10550. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.10550.

Повний текст джерела

Анотація:

10550 Background: Despite the human papillomavirus (HPV) vaccine being safe and effective at preventing HPV-associated cancers, vaccine update is low. Several factors have been identified as barriers to getting the HPV vaccine. However, it is unclear if these factors have changed since vaccine licensure. Thus, we assessed trends in the top five reasons for vaccine hesitancy in the last decade in the US. Methods: We analyzed the 2010–2019 National Immunization Survey–Teen data, a national survey representative of the US adolescent population. We identified adolescents (n = 16,383) who had recei

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!